University of California, San Francisco
Investigators believe that patients with cervical spondylotic myelopathy (CSM) have measurable changes in certain molecules in their blood compared with people without CSM. Investigators expect that these changes may be related to how severe a patient's condition is based on imaging and clinical exams. Investigators will also study how these molecules change before and after surgery to see whether they are related to how well patients recover. By combining these blood markers with clinical and imaging information, investigators hope to develop a tool that may help predict patient outcomes.
Cervical spondylotic myelopathy (CSM) represents the most common cause of non-traumatic spinal cord injury in adults (New et al., 2014) with an estimated prevalence of 605 per million in North America (Nouri et al., 2015). This degenerative condition leads to spinal cord compression which can result in severely debilitating symptoms such as weakness, loss of fine motor control, bowel and bladder dysfunction, and pain. Surgical decompression is often needed in patients with symptomatic neural element stenosis, and surgical decision-making is primarily based on clinical examination findings and…
Healthy Inclusion Criteria: * Age \>18 * No neck pain * No radiculopathy or myelopathy symptoms * No trauma in the past 6 months * Does not meet exclusion criteria. CSM Inclusion Criteria: * Age \>18 * Diagnosis of/encompassed by/related to cervical spondylotic myelopathy, cervical myelopathy, ossification of posterior longitudinal ligament. Healthy Exclusion Criteria: * Age \<18. * Malignancy * Trauma in the past 6 months * Infectious etiology * Prior cervical spine surgery. * Symptoms of cervical radiculopathy, myelopathy or neck pain. CSM Exclusion Criteria: * Age \<18. * Malignancy…
Arctuva estimate
Verify or correct the compensation shown for this listing.